Home/Filings/4/0000909518-09-000164
4//SEC Filing

BHAGWAT DILEEP 4

Accession 0000909518-09-000164

CIK 0001208261other

Filed

Feb 23, 7:00 PM ET

Accepted

Feb 24, 8:18 PM ET

Size

6.1 KB

Accession

0000909518-09-000164

Insider Transaction Report

Form 4
Period: 2009-02-20
BHAGWAT DILEEP
SVP-Pharmaceutical Development
Transactions
  • Award

    Stock Option (right to buy)

    2009-02-20+130,000615,965 total
    Exercise: $0.56Exp: 2019-02-20Common Stock, par value $0.0001 per share (130,000 underlying)
Footnotes (2)
  • [F1]The options shall vest in increments upon the achievement of each of the following business objectives: the completion of a Ceplene marketing agreement(s); the completion of a licensing agreement for NP-1; obtaining market approval for Ceplene in the United States; and obtaining market approval for Ceplene in Canada. The exercise of these options is subject to shareholder approval of an increase in the number of shares available under the 2005 Equity Incentive Plan.
  • [F2]No consideration was given since option was granted pursuant to a stock option agreement.

Issuer

EPICEPT CORP

CIK 0001208261

Entity typeother

Related Parties

1
  • filerCIK 0001141757

Filing Metadata

Form type
4
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 8:18 PM ET
Size
6.1 KB